Published in J Virol on July 01, 2001
Nucleotide sequence of Rous sarcoma virus. Cell (1983) 17.80
An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J Virol (1994) 5.87
Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J Virol (1995) 5.21
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells. J Virol (1989) 4.60
Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A (2000) 4.31
Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src. J Virol (1991) 4.25
A role for ubiquitin ligase recruitment in retrovirus release. Proc Natl Acad Sci U S A (2000) 4.19
Properties of avian retrovirus particles defective in viral protease. J Virol (1990) 4.03
Self-assembly of purified polyomavirus capsid protein VP1. Cell (1986) 4.00
Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A (2000) 3.83
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol (1993) 3.19
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
Polymorphism in the assembly of polyomavirus capsid protein VP1. Biophys J (1989) 2.74
A domain of SV40 capsid polypeptide VP1 that specifies migration into the cell nucleus. EMBO J (1986) 2.51
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue. J Virol (1998) 2.18
Mass determination of rous sarcoma virus virions by scanning transmission electron microscopy. J Virol (1999) 2.15
Site-directed mutation affecting polyomavirus capsid self-assembly in vitro. Nature (1987) 1.75
Nuclear assembly of polyomavirus capsids in insect cells expressing the major capsid protein VP1. J Virol (1991) 1.70
Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67
Release of simian virus 40 virions from epithelial cells is polarized and occurs without cell lysis. J Virol (1989) 1.66
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43
The membrane-binding domain of the Rous sarcoma virus Gag protein. J Virol (1996) 1.39
Characterization of a nuclear localization sequence in the polyomavirus capsid protein VP1. Virology (1991) 1.23
Analysis of a nuclear localization signal of simian virus 40 major capsid protein Vp1. J Virol (1996) 1.21
Nucleotide sequence and translation of satellite tobacco mosaic virus RNA. Virology (1989) 1.16
Conditions for copackaging rous sarcoma virus and murine leukemia virus Gag proteins during retroviral budding. J Virol (1999) 1.07
Altered Rous sarcoma virus Gag polyprotein processing and its effects on particle formation. J Virol (1997) 1.05
Analysis of genetic heterogeneity within the type strain of satellite tobacco mosaic virus reveals variants and a strong bias for G to A substitution mutations. Virology (1992) 0.98
Structural comparison of the plant satellite viruses. Virology (1995) 0.93
A simple qualitative spot complementation test for temperature-sensitive mutants of SV40. Intervirology (1974) 0.90
Transport and processing of the Rous sarcoma virus Gag protein in the endoplasmic reticulum. J Virol (1996) 0.86
Form, function, and use of retroviral gag proteins. AIDS (1991) 9.24
Identification of a membrane-binding domain within the amino-terminal region of human immunodeficiency virus type 1 Gag protein which interacts with acidic phospholipids. J Virol (1994) 6.67
Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins. J Virol (1995) 4.92
DNA content, kinetic complexity, and the ploidy question in Candida albicans. Mol Cell Biol (1982) 4.64
Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein. J Virol (1997) 4.08
Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain. J Virol (1996) 3.97
Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A (2000) 3.83
Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins. J Virol (1993) 3.71
Incorporation of chimeric gag protein into retroviral particles. J Virol (1990) 3.43
Characterization of a small (25-kilodalton) derivative of the Rous sarcoma virus Gag protein competent for particle release. J Virol (1993) 3.19
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
WW domains and retrovirus budding. Nature (1996) 3.10
Late domain function identified in the vesicular stomatitis virus M protein by use of rhabdovirus-retrovirus chimeras. J Virol (1999) 2.90
Genetic analysis of the major homology region of the Rous sarcoma virus Gag protein. J Virol (1995) 2.76
Repetitive DNA of Candida albicans: nuclear and mitochondrial components. J Bacteriol (1984) 2.52
Necessity of the spacer peptide between CA and NC in the Rous sarcoma virus gag protein. J Virol (1993) 2.40
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Role of the avian retroviral protease in the activation of reverse transcriptase during virion assembly. J Virol (1991) 2.23
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue. J Virol (1998) 2.18
A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles. J Virol (1995) 1.93
Intracellular trafficking of the UL11 tegument protein of herpes simplex virus type 1. J Virol (2001) 1.90
Circular mitochondrial genome of Candida albicans contains a large inverted duplication. J Bacteriol (1985) 1.84
Evidence for a second function of the MA sequence in the Rous sarcoma virus Gag protein. J Virol (1996) 1.70
Efficiency and selectivity of RNA packaging by Rous sarcoma virus Gag deletion mutants. J Virol (1994) 1.70
Genetic determinants of Rous sarcoma virus particle size. J Virol (1998) 1.67
Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions. J Virol (2001) 1.55
Particle size determinants in the human immunodeficiency virus type 1 Gag protein. J Virol (1998) 1.48
Recent advances and remaining problems in HIV assembly. AIDS (1998) 1.46
A large region within the Rous sarcoma virus matrix protein is dispensable for budding and infectivity. J Virol (1996) 1.43
The membrane-binding domain of the Rous sarcoma virus Gag protein. J Virol (1996) 1.39
Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera. J Virol (2000) 1.36
Myristylation of Rous sarcoma virus Gag protein does not prevent replication in avian cells. J Virol (1990) 1.36
Repositioning basic residues in the M domain of the Rous sarcoma virus gag protein. J Virol (2000) 1.33
Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31
Identification of retroviral late domains as determinants of particle size. J Virol (1999) 1.25
Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol (1986) 1.21
Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proc Natl Acad Sci U S A (1995) 1.18
RNA dimerization defect in a Rous sarcoma virus matrix mutant. J Virol (2000) 1.18
Expression of the Rous sarcoma virus env gene from a simian virus 40 late-region replacement vector: effects of upstream initiation codons. J Virol (1987) 1.18
Molecular cloning of the Mason-Pfizer monkey virus genome: characterization and cloning of subgenomic fragments. Virology (1985) 1.08
Conditions for copackaging rous sarcoma virus and murine leukemia virus Gag proteins during retroviral budding. J Virol (1999) 1.07
Transport and processing of the Rous sarcoma virus Gag protein in the endoplasmic reticulum. J Virol (1996) 0.86
The major site of phosphorylation within the Rous sarcoma virus MA protein is not required for replication. J Virol (1998) 0.84
Automation and validation of micronucleus detection in the 3D EpiDerm™ human reconstructed skin assay and correlation with 2D dose responses. Mutagenesis (2014) 0.77
Esophagoscopy. An analysis of two hundred cases. Med Ann Dist Columbia (1966) 0.75